Clinical trial
An Open Label, Phase I/II Dose Escalating Study Evaluating the Safety and Efficacy of EPO906, qw3, in Patients With Non-small Cell Lung Cancer.
NCT00171834 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label, Phase I/II Dose Escalating Study Evaluating the Safety and Efficacy of EPO906, qw3, in Patients With Non-small Cell Lung Cancer.
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- August 31, 2003
- Completion date
- September 30, 2008
- Enrollment
- 89 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.